Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003

摘要

Objectives: The objective of this analysis was to estimate costs for lung cancer care and evaluate trends in the share of treatment costs that are the responsibility of Medicare beneficiaries. Methods: The Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 1991-2003 for 60,231 patients with lung cancer were used to estimate monthly and patientliability costs for clinical phases of lung cancer (prediagnosis, staging, initial, continuing, and terminal), stratified by treatment, stage, and non-small-versus small-cell lung cancer. Lung cancer-attributable costs were estimated by subtracting each patient's own prediagnosis costs. Costs were estimated as the sum of Medicare reimbursements (payments from Medicare to the service provider), co-insurance reimbursements, and patient-liability costs (deductibles and "co-payments" that are the patient's responsibility). Costs and patientliability costs were fit with regression models to compare trends by calendar year, adjusting for age at diagnosis. Results: The monthly treatment costs for a 72-year-old patient, diagnosed with lung cancer in 2000, in the first 6 months ranged from $2687 (no active treatment) to $9360 (chemoradiotherapy); costs varied by stage at diagnosis and histologic type. Patient liability represented up to 21.6 of care costs and increased over the period 1992-2003 for most stage and treatment categories, even when care costs decreasedorremained unchanged. The greatest monthly patient liability was incurred by chemo-radiotherapy patients, which ranged from $1617 to $2004 per month across cancer stages. Conclusions: Costs for lung cancer care are substantial, and Medicare is paying a smaller proportion of the total cost over time.